Alnylam buys Merck's Sirna Therapeutics

Alnylam Pharmaceuticals has acquired Merck's subsidiary Sirna Therapeutics, comprising intellectual property and RNAi assets, including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news